RSLS_OUT_1 [2025-04-04 10:02:04 -0400] 3438 Bytes | 920 tokens | Cum: 920 tkns (11.50% of 8k)
==========================================================================

Listen up, partner—it's 10:02:03 AM on Fri Apr 04, 2025 -0400, and I’m revved up about ReShape Lifesciences (RSLS), climbing from 0.3797 to 0.4662. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: ReShape Lifesciences (RSLS)
IPO: 2021-06-16 (3 Years Ago)
Market Cap: $5,255,088
Shares Outstanding: 3,310,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Here’s the first list of news for ReShape Lifesciences:

C1 - Mar-10-25 08:31AM - ReShape Lifesciences Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
C2 - Feb-25-25 08:31AM - ReShape Lifesciences Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band 2.0 FLEX
C3 - Feb-15-25 11:17PM - ReShape Lifesciences Announces Pricing of Upsized $6.0 Million Public Offering
C4 - Feb-03-25 08:31AM - ReShape Lifesciences Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
C5 - Jan-13-25 08:31AM - ReShape Lifesciences Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
C6 - Nov-14-24 04:05PM - ReShape Lifesciences Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
C7 - Nov-12-24 04:05PM - ReShape Lifesciences to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
C8 - Nov-12-24 04:05PM 08:31AM - ReShape Lifesciences Receives Health Canada Approval for its Next-Generation Lap-Band 2.0 FLEX

Prior AI Reports for RSLS:
1. 2025-04-01 – Score: 20 – Target: 0.8455 – Highs: 3.0500 / 0.7018 / 0.43
struggling-company-sees-glimmer-of-hope-amid-sales-growth

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: ReShape Lifesciences (RSLS).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

RSLS_OUT_3 [2025-04-04 10:02:09 -0400] 1107 Bytes | 331 tokens | Cum: 1254 tkns (15.68% of 8k)
==========================================================================

Showing C3 (chunk 1 of 8): C3:
**ReShape Lifesciences Announces Pricing of Upsized $6.0 Million Public Offering**
Date: Feb-15-25 11:17PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/02/16/3026963/0/en/ReShape-Lifesciences-Announces-Pricing-of-Upsized-6-0-Million-Public-Offering.html

February 15, 2025 23:17 ET| Source:ReShape Lifesciences IncReShape Lifesciences Inc

IRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) --ReShape Lifesciences®(“ReShape” or the “Company”)(Nasdaq: RSLS),the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 2,575,107 units at a public offering price of $2.33 per unit. Each unit consists of one common share (or pre-funded warrant to purchase one common share in-lieu thereof) and one warrant to purchase one common share.

The warrants, which are not exercisable unless and until app

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_5 [2025-04-04 10:02:10 -0400] 989 Bytes | 296 tokens | Cum: 1638 tkns (20.47% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-04T10:40:20Z - North American Morning Briefing: Stock Futures -2-...
A2 - 2025-04-02T17:06:16Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Allakos (NASDAQ:ALLK), Alumis (NASDAQ...
A3 - 2025-04-02T14:07:50Z - Nasdaq Tumbles 100 Points; UniFirst Posts Upbeat Earnings - ConnectM Technology (NASDAQ:CNTM), Digit...
A4 - 2025-04-02T12:05:45Z - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Enzo Biochem (NYSE:ENZ), Curis (NAS...
A5 - 2025-04-02T08:57:22Z - Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premark...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RSLS_OUT_7 [2025-04-04 10:02:16 -0400] 1098 Bytes | 325 tokens | Cum: 1965 tkns (24.56% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**North American Morning Briefing: Stock Futures -2-**Date: 2025-04-04Source: {'uri': 'morningstar.com', 'dataType': 'news', 'title': 'Morningstar'}URL: https://www.morningstar.com/news/dow-jones/202504042473/north-american-morning-briefing-stock-futures-2Dominari Holdings Inc (DOMH) is expected to report for 4Q.

Genprex Inc (GNPX) is expected to report for 4Q.

InnSuites Hospitality Trust (IHT) is expected to report for 4Q.

Karnalyte Resources (KRLTF,KRN.T) is expected to report for 4Q.

Patriot National Bancorp Inc (PNBK) is expected to report for 4Q.

ReShape Lifesciences Inc (RSLS) is expected to report for 4Q.

AllianceBernstein Holding Cut to Neutral From Buy by B of A Securities

Best Buy Cut to Neutral From Buy by Citigroup

BJ's Wholesale Club Raised to Buy From Neutral by Citigroup

Block Raised to Overweight From Equal-Weight by Morgan Stanley

Eastman Chemical Raised to

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_9 [2025-04-04 10:02:23 -0400] 1098 Bytes | 269 tokens | Cum: 2346 tkns (29.33% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): Outperform From Neutral by Mizuho

Edgewise Therapeutics Cut to Sector Perform From Sector Outperform by Scotiabank

Hayward Holdings Cut to Peer Perform From Outperform by Wolfe Research

Loar Holdings Raised to Overweight From Equal-Weight by Morgan Stanley

Parker-Hannifin Cut to Peer Perform From Outperform by Wolfe Research

ProAssurance Cut to Market Perform From Market Outperform by Citizens Capital Markets

RH Cut to Neutral From Buy by Citigroup

Ross Stores Raised to Buy From Neutral by Citigroup

Sachem Capital Cut to Neutral From Buy by Ladenburg Thalmann

TJX Cos Raised to Buy From Neutral by Citigroup

US Bancorp Cut to Underweight From Neutral by JP Morgan

US Bancorp Raised to Outperform From Peer Perform by Wolfe Research

WW Grainger Raised to Peer Perform From Underperform by Wolfe Research

Zscaler Raised to Overweight From Neutral by Cantor Fitzgerald

This article

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_11 [2025-04-04 10:02:25 -0400] 278 Bytes | 84 tokens | Cum: 2558 tkns (31.97% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): is a text version of a Wall Street Journal newsletter published earlier today.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_13 [2025-04-04 10:02:27 -0400] 1031 Bytes | 315 tokens | Cum: 2910 tkns (36.38% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-23T22:59:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders
B2 - 2025-02-16T04:17:00Z - ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
B3 - 2025-01-13T13:31:00Z - ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
B4 - 2024-07-09T12:32:57Z - ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With ... - GlobeNewswire
B5 - 2024-05-30T10:54:00Z - Investing in AI Penny Stocks? 3 Top Tips
B6 - 2024-05-15T20:05:00Z - ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RSLS_OUT_15 [2025-04-04 10:02:30 -0400] 720 Bytes | 210 tokens | Cum: 3122 tkns (39.02% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/16/3026963/0/en/ReShape-Lifesciences-Announces-Pricing-of-Upsized-6-0-Million-Public-Offering.htmlReShape Lifesciences, a weight loss and metabolic health solutions company, announced the pricing of its public offering of 2,575,107 units at $2.33 per unit. The offering is expected to raise approximately $6.0 million in gross proceeds.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_17 [2025-04-04 10:02:31 -0400] 1123 Bytes | 300 tokens | Cum: 3480 tkns (43.50% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-20 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 15, 2025, ReShape Lifesciences Inc. (the Company) entered into a Securities Purchase Agrmt (the Purchase Agrmt) with certain investors (the Investors) pursuant to which the Company agreed to issue and sel...

S2 - 2025-02-20 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 15, 2025, ReShape Lifesciences Inc. (the Company) entered into a Securities Purchase Agrmt (the Purchase Agrmt) with certain investors (the Investors) pursuant to which the Company agreed to issue and sel...

S3 - 2025-01-21 8-K Item 1.01 Entry into a Material Definitive Agrmt.

As previously disclosed, on October 16, 2024, ReShape Lifesciences Inc. (the Company) entered into a securities purchase agreement (the SPA) with Ascent Partners Fund LLC, an institutional investor (the Investor). Pursuant t...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RSLS_OUT_19 [2025-04-04 10:02:36 -0400] 1098 Bytes | 299 tokens | Cum: 3781 tkns (47.26% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01 Entry into a Material Definitive Agreement.

On February 15, 2025, ReShape Lifesciences Inc. (the Company) entered into a Securities Purchase Agreement (the Purchase Agreement) with certain investors (the Investors) pursuant to which the Company agreed to issue and sell to the Investors (i) 2,575,107 shares of the Companys common stock, par value $0.001 per share (the Common Stock) and (ii) warrants to purchase up to 2,575,107 shares of Common Stock at an initial exercise price of $5.83 per share (the Warrants), subject to adjustment as set forth in the Warrants. The securities were sold as part of units at a price of $2.33 per unit. The offering closed on February 18, 2025.

The Warrants, which are not exercisable unless and until approved by the Companys stockholders, will expire on the later of (i) 12 days after date of stockholder approval and (ii) the earlier of (x) t

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_21 [2025-04-04 10:02:48 -0400] 4790 Bytes | 1323 tokens | Cum: 5230 tkns (65.38% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+------------------------+
| Volume: 1,165,170 | Perf Month: -61.12% | Option/Short: No / Yes | Sales Y/Y TTM: -16.55% |
+-------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 6.74M | Perf Quarter: -91.89% | Short Float: 13.55% | ROE: -309.28% |
+-------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 1.94 | Index: - | Short Ratio: 0.05 | ROI: -451.85% |
+-------------------+-----------------------+------------------------+------------------------+
| RSI (14): 39.77 | Market Cap: 1.22M | Short Interest: 0.37M | Sales Surprise: - |
+-------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.34 | Shs Outstand: 3.31M | Beta: 1.41 | EPS Surprise: - |
+-------------------+-----------------------+------------------------+------------------------+
| SMA20: -39.58% | Shs Float: 2.71M | Sales Q/Q: 6.36% | P/E: - |
+-------------------+-----------------------+------------------------+------------------------+
| SMA50: -77.23% | Inst Own: 1.01% | Sales past 5Y: - | Earnings: Nov 14 AMC |
+-------------------+-----------------------+------------------------+------------------------+
| SMA200: -93.96% | Insider Own: 18.08% | Employees: - | |
+-------------------+-----------------------+------------------------+------------------------+
| Perf Week: -4.37% | Insider Trans: 0.00% | Debt/Eq: 0.13 | |
+-------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading if any are accessible.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 2292000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1581000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.4819
Average Volume: 15350158.78
30-Day High: 1.59
30-Day Low: 0.3605

[Detailed Financials: Q3 2024]
- Total Assets: $5,615,000.0
- Total Liabilities: $4,128,000.0
- Total Equity: $1,487,000.0
- Current Assets: $5,338,000.0
- Current Liabilities: $4,025,000.0

[Income Statement: Q3 2024]
- Revenue: $2,292,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3.11

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $6,393,000.0
- Total Liabilities: $3,358,000.0
- Total Equity: $3,035,000.0
- Current Assets: $6,087,000.0
- Current Liabilities: $3,201,000.0

[Income Statement: Q2 2024]
- Revenue: $1,965,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.06

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $2,072,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

RSLS_OUT_23 [2025-04-04 10:02:53 -0400] 687 Bytes | 169 tokens | Cum: 5661 tkns (70.76% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

RSLS_IN_25 [2025-04-04 10:02:53 -0400] 126 Bytes | 29 tokens | Cum: 5720 tkns (71.50% of 8k)
==========================================================================

====================================
[2025-04-04 10:02:53] # Analysis Completed
Elapsed Time: 50.16 seconds